Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy - Report - MDSpire

Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy

  • By

  • Zichao You

  • Li Jiang

  • Ying-rui Liu

  • Ming Ming Yang

  • June 23, 2026

  • 0 min

Share

Clinical Report: Individualized Treatment Approaches for Diabetic Macular Edema

Background

Diabetic macular edema is a leading cause of visual impairment among adults with diabetes. Despite the effectiveness of anti-VEGF therapies, a significant proportion of patients do not achieve optimal anatomical or functional outcomes. Understanding the diverse pathophysiological mechanisms of DME is crucial for developing tailored treatment strategies.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Multimodal imaging techniques, including OCT, OCTA, and UWF-FA, enhance the characterization of retinal changes in DME.
  • Two domains of imaging biomarkers were identified: markers of disease activity and predictors of visual prognosis.
  • DME can be classified into five clinical phenotypes based on distinct biomarker profiles.
  • Proposed decision-support framework includes baseline evaluation, phenotype classification, and dynamic optimization of treatment.
  • Future advancements may include automated biomarker quantification and AI-assisted image analysis for improved DME management.

Clinical Implications

The proposed phenotype-based classification system may guide clinicians in selecting appropriate therapeutic interventions for DME. Utilizing multimodal imaging can help identify patients who may benefit from alternative treatments beyond standard anti-VEGF therapy.

Conclusion

Integrating multimodal imaging and phenotype classification into clinical practice may lead to more individualized and effective management of diabetic macular edema.

Related Resources & Content

  1. Virginia Pickles, Retinal Physician, 2015 -- Changing Treatment Paradigms in Diabetic Macular Edema
  2. Jack Persico, Retinal Physician, 2009 -- RPS: From the Podium to the Practice
  3. Michael Coluccielo, Retinal Physician, 2010 -- Treating Macular Edema
  4. Retinal Physician, 2026 -- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes
  5. ScienceDirect, 2026 -- Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial
  6. ScienceDirect, 2025 -- Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial
  7. PubMed, 2023 -- Disorganization of inner retinal layers and disruption of outer retinal layers as predictors of anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema: A scoping review
  8. Retinal Physician — Advancing Treatments for Diabetic Macular Edema
  9. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 - PMC
  10. Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial - ScienceDirect
  11. Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial - ScienceDirect
  12. Disorganization of inner retinal layers and disruption of outer retinal layers as predictors of anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema: A scoping review - PubMed

Original Source(s)

Related Content